Citius Oncology, Inc. (CTOR)
Nasdaq: CTOR · Pharmaceutical Preparations · Cranford, NJ · filing with the SEC since 2021
Who owns Citius Oncology, Inc.
As filed with the SECHolders of 5% or more
2
Citius Pharmaceuticals, Inc. holds 71% of Common Shares, $0.0001 par value per share, as its SCHEDULE 13D/A filed Jun 4, 2026 says.
Directors and officers
11
report now, of 15 people on the record since 2022. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Citius Pharmaceuticals, Inc.
SCHEDULE 13D/A · filed Jun 4, 2026 · Common Shares, $0.0001 par value per share · 77.9% in Dec 17, 2025
Armistice Capital, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 9.99% in May 15, 2026
What CTOR reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Citius Pharma
An investee · investee, related party · invested in, named in the 10-K filed Dec 23, 2025
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 12, 2025 to Nov 12, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
No open-market trade is on the record for these years.
Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.